Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial

IMPORTANCE: Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable effective therapies. OBJECTIVE: To assess the efficacy and safety of a combination of pembrolizumab with bevacizumab and o...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:JAMA Oncol
Hoofdauteurs: Zsiros, Emese, Lynam, Sarah, Attwood, Kristopher M., Wang, Chong, Chilakapati, Shanmuga, Gomez, Eduardo Cortes, Liu, Song, Akers, Stacey, Lele, Shashikant, Frederick, Peter J., Odunsi, Kunle
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Medical Association 2020
Onderwerpen:
Original Investigation
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7677872/
https://ncbi.nlm.nih.gov/pubmed/33211063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.5945
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items